Table 1 Selected genomics drugs in clinical development
Drug | Drug target | Associated genomics company during discovery phase | Indication* | Phase* |
|---|---|---|---|---|
Belimumab | BLYS | Human Genome Sciences | Systemic lupus erythematosus | Preregistration |
Atacicept | BLYS receptor | ZymoGenetics | Systemic lupus erythematosus | II/III |
Mapatumumab | TRAIL-R1 | Human Genome Sciences | Cancer | II |
Apomab | TRAIL-R2 | Genentech | Cancer | II |
Dulanermin | TRAIL | Amgen/Genentech | Cancer | II |
Odanacatib | Cathepsin K | Celera | Postmenopausal osteoporosis | III |
AMG-785 | Sclerostin | Amgen | Postmenopausal osteoporosis | II |
DG-041 | Prostanoid EP3 receptor (antagonist) | deCODE Genetics | Peripheral arterial obstructive disease | II |
OC-000459 | CRTH2 receptor (antagonist) | Oxagen | Asthma | II |
PLX-4032 | BRAF kinase | Plexxikon | Metastatic melanoma | III |
LX-1031 | TPH1 | Lexicon Pharmaceuticals | Irritable bowel syndrome | II |
LX-1032 | TPH1 | Lexicon Pharmaceuticals | Carcinoid syndrome | II |
BLYS, B lymphocyte stimulator (also known as TNFSF13B/BAFF); TPH1, tryptophan hydroxylase 1; TRAIL-R1, TNF-related apoptosis inducing ligand (TRAIL) receptor 1 (also known as DR4/TNFRSF10A); TRAIL-R2, also known as DR5/TNFRSF10B.*Data extracted from Thomson Reuters Integrity database on 28 September 2010. | ||||
